Lilly has made a significant move by securing a $7 billion deal with Kelonia to enhance its in vivo CAR-T oncology pipeline, a strategic investment that could bolster its position in the competitive biotech landscape. This development comes as investors closely monitor the company’s valuation and future earnings potential.
In other market news, infrastructure stocks have outperformed expectations, reporting Q4 revenue growth of 11.8%, leading to a 7.9% rise in shares. Meanwhile, QXO’s acquisition of TopBuild for $17 billion at a 23.1% premium highlights continued M&A activity, valuing TopBuild at 14.9 times EBITDA. Oil prices surged 4% to $87 per barrel amid geopolitical tensions in the Strait of Hormuz, while the Dow dipped slightly.
A key takeaway for market professionals is the tightening of agency MBS spreads, which may present mid-teen return on equity opportunities, signaling potential shifts in fixed-income strategies amidst evolving market conditions.
Source: investinglive.com